Two Asian markets moved on the same drug in the same week and split. The split has nothing to do with the drug. It is a clean demonstration of which endpoint each kind of body is willing to act on.

• Regulators approve on progression, payers pay on survival. Singapore’s regulator cleared both regimens on PFS. Korea’s payer funded the one carrying an OS hazard ratio of 0.58 and declined the one whose median PFS was still not reached at 21.8 months. Read that as the pricing bar, not a safety judgement.
• The regimen left outside coverage serves the harder patients. DREAMM-8 enrolled 78% lenalidomide-refractory patients and 25% with prior daratumumab. In Korea, the patients with the fewest remaining options are the ones without funding. Expect that gap to be the argument at resubmission.
• Ocular monitoring is a siting constraint, not a footnote. MFDS requires visual acuity and slit-lamp examination by an ophthalmologist before every cycle, at institutions able to coordinate that care. Discontinuation for eye events stayed at or below 9% in both trials, but only where that pathway exists. Model centre eligibility before volume.